NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.41 -0.01 (-3.37%) Closing price 04:00 PM EasternExtended Trading$0.41 +0.01 (+1.72%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxart Stock (NASDAQ:VXRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxart alerts:Sign Up Key Stats Today's Range$0.39▼$0.4350-Day Range$0.42▼$0.8252-Week Range$0.39▼$1.34Volume2.33 million shsAverage Volume1.92 million shsMarket Capitalization$92.78 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More… Remove Ads Vaxart Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreVXRT MarketRank™: Vaxart scored higher than 44% of companies evaluated by MarketBeat, and ranked 659th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.52% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Vaxart has recently decreased by 7.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.52% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Vaxart has recently decreased by 7.91%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.44 News SentimentVaxart has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Vaxart this week, compared to 1 article on an average week.Search Interest9 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows15 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 88% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesB. Riley Comments on Vaxart's Q1 Earnings (NASDAQ:VXRT)March 31 at 1:17 AM | americanbankingnews.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.March 31, 2025 | Golden Portfolio (Ad)Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart, Inc. (NASDAQ:VXRT) Sees Significant Growth in Short InterestMarch 21, 2025 | americanbankingnews.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comVaxart Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.6621 on January 1st, 2025. Since then, VXRT stock has decreased by 36.7% and is now trading at $0.4190. View the best growth stocks for 2025 here. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) announced its quarterly earnings data on Thursday, March, 20th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. The biotechnology company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $15.68 million. Vaxart had a negative trailing twelve-month return on equity of 110.46% and a negative net margin of 431.61%. When did Vaxart's stock split? Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. Who are Vaxart's major shareholders? Vaxart's top institutional investors include Millennium Management LLC (1.31%), Geode Capital Management LLC (1.14%), Silverarc Capital Management LLC (0.47%) and Squarepoint Ops LLC (0.23%). Insiders that own company stock include W Mark Watson and Fuad Ahmad. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings3/20/2025Today3/31/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+612.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-431.61% Pretax Margin-430.07% Return on Equity-110.46% Return on Assets-62.78% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual Sales$28.70 million Price / Sales3.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.11Miscellaneous Outstanding Shares227,949,000Free Float221,566,000Market Cap$96.01 million OptionableOptionable Beta1.69 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:VXRT) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredAI Boom Takes a Shocking Turn…AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.